drugset / Trial / NCT04995042
A Phase 1 Dose Escalation and Expansion Study Of SHR7280 In Subjects With Hormone Sensitive Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, multicenter, dose escalation and expansion Phase 1 study of SHR7280 in adult patients with hormone sensitive prostate cancer.
Timeline
- Start
- 2021-09-24
- Primary completion
- 2023-05-24
- Completion
- 2023-05-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SHR7280 | Small molecule | — | — |
Indications
No indication recorded.